Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

GVDs for pharmaceutical companies

- PMLiVE

GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension

PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide

- PMLiVE

The race to explore and harness GenAI in healthcare

AI has graduated from being a procurer of efficiencies to seemingly an enabler of unimagined possibilities

- PMLiVE

The ‘jagged frontier’, straight talk and why humans still matter

By Matthew Hunt

- PMLiVE

Novo Nordisk to lower list price, or wholesale acquisition cost, for Wegovy and Ozempic

The reduction in price to $675 will take effect at the beginning of next year

- PMLiVE

Incyte Biosciences UK announces NICE approval for Opzelura for vitiligo

This is the first approved treatment option in the UK for patients with non-segmental vitiligo

Grace Communications logo

T40: when a number is not just a number

Proud to be ranked 3rd among the Top 10 UK-focused agencies, along with other categories, Grace Communications finds inspiration in being included in PMLive’s Top 40 Creative Healthcare Agencies 2025.

Grace Communications

- PMLiVE

Copenhagen Airports A/S, SAS Cargo and World Courier to host FlyPharma 2026

The conference will take place from 6 to 7 October 2026 in Copenhagen, Denmark

- PMLiVE

Gilead to acquire Arcellx in deal worth $7.8bn

The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma

phthalmologist, optometrist checking child, little girl vision looking for problems and caring for eye

Why patient engagement must come first in rare disease trials

Explore why patient engagement is the cornerstone of successful rare disease trials, emphasising the importance of designing studies around the realities of patients' lives to build trust and improve outcomes.

Cuttsy + Cuttsy

Fan image of Site Report

New Cuttsy+Cuttsy research shows why site support matters more than ever

Cuttsy+Cuttsy's upcoming report, 'The site factor: Where protocol meets practice in clinical trials', delves into the critical role of site staff in clinical research, offering insights into their daily challenges,...

Cuttsy + Cuttsy

- PMLiVE

PureTech’s deupirfenidone gets FDA and EC Orphan Drug Designations for idiopathic pulmonary fibrosis

Rare diseases are defined as conditions affecting fewer than 200,000 people in the US or fewer than five in 10,000 individuals in the European Union

- PMLiVE

CGT Catapult establishes Technology Advisory Board led by chair Phil Vanek

The board will support the CGT Catapult in identifying and removing barriers to the widespread adoption of advanced therapies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links